ChiefExecutive.net

Ziopharm Oncology: A New Approach to New Drugs

For a little biopharmaceutical company, Ziopharm Oncology has attracted capital from some heavy hitters—a coup in an industry hit particularly hard by the financial market crunch. Here, Chief Executive interviews CEO Jonathan Lewis.

Ziopharm Oncology’s CEO Jonathan Lewis Takes a New Approach to New Drugs

For a little biopharmaceutical company, Ziopharm Oncology has attracted capital from some heavy hitters—a coup in an industry hit particularly hard by the financial market crunch. Here, Chief Executive interviews CEO Jonathan Lewis.

Winning in Windsor

Two years into his reign at the helm of InterContinental Hotels Group (IHG) and Andrew Cosslett can still get worked [...]

Winning in a Multicultural Market

Long heralded, the phenomenal potential of multicultural markets is now undeniably upon Corporate America. Hispanics accounted for about half of [...]

Who’s On Next?

Marv Soiland, president and founder of Stony Point Rock Quarry, was in his 70s when the issue of a successor [...]

Who You Gonna Call?

Robert S. “Steve” Miller, 66, gained a reputation for fixing ailing companies, something that became an unantici – pated career [...]

When E-brands FAIL: Building Hew Brand Value with Old Brand Tricks

What’s in a Name?

As an AT&T veteran, Embarq CEO Daniel Hesse well knows the power a strong brand can wield. “I grew up [...]

What’s Next for China?

Already the world’s second-largest economy, China’s future—and the future of companies doing business there—depends on overcoming significant hurdles.Here’s what CEOs had to say at a roundtable at the CEO of the Year.

What is Wrong With CEO Succession?

Dropping for decades, the typical tenure of a CEO is now between four and five years. In fact, business leaders [...]